Abstract
The present study describes development of 3D-QSAR on anti-trypanosomal activity based on selected pharmacophore hypothesis. The 3-nitro-1H-1,2,4-triazole-aliphatic and aromatic amines analogs have been selected for its anti-trypanosomal activity using PHASE. The present works also comprises molecular interaction study of 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines analogs on maestro 8.5 workstation. Anti-trypanosomal activities on various strains, e.g., L. donovani, T.b. rhodesiense, and T. Cruzi, of 3-nitro-1H-1,2,4-triazole-aliphatic and aromatic amines analogs have been reported in the literature. The 3D-QSAR study on Phase module comprises the five-point pharmacophore models for the anti-protozoan parasites activities, e.g., L. donovani (AGHRR.1009), T.b. rhodesiense (AGHRR.1604), and T. Cruzi (ADHRR.1067). The developed pharmacophore models on anti-protozoan activities share the common features, viz. consisting of one hydrogen bond acceptor (A), one hydrogen bond donor (D), one Hydrophobic (H), and two aromatic ring (R) as pharmacophoric feature. The diagnostic statics of selected 3D QSAR models shown the good predictive nature, e.g., correlation coefficient value (r 2 < 0.99), which is well anticipated by good cross-validated correlation coefficient (q 2 < 0.6). The QSAR models suggest that hydrophobic and aromatic characters are crucial for the anti-trypanosomal activities. The QSAR models also suggest that the inclusion of hydrophobic substituents would enhance the anti-trypanosomal activities. In addition, the hydrogen bond acceptor and hydrophobic character contribute positively to the anti-trypanosomal activities. The present study provides a set of guideline for rational drug design with more optimized agents based on predictive 3D-QSAR models for better anti-trypanosomal activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agrawal R, Jain P, Dikshit SN, Jain S (2013) 3D QSAR and docking studies of various amido and benzyl-substituted 3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl analogs as DPP-IV inhibitors. Protein Pept Lett 20(9):1066–1078
Athri P, Wenzler T, Ruiz P, Brun R, Boykin DW, Tidwell R et al (2006) 3D QSAR on a library of heterocyclic diamidine derivatives with antiparasitic activity. Bioorg Med Chem 14(9):3144–3152
Augustyns K, Amssoms K, Yamani A, Rajan PK, Haemers A (2001) Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents. Curr Pharm Des 7(12):1117–1141
Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ et al (2003) The trypanosomiases. Lancet 362(9394):1469–1480
Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO et al (2007) Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 298(18):2171–2181
Castro JA, de Mecca MM, Bartel LC (2006) Toxic side effects of drugs used to treat Chagas’ disease (American trypanosomiasis). Hum Exp Toxicol 25(8):471–479
Chatelain E, Ioset JR (2011) Drug discovery and development for neglected diseases: the DNDi model. Drug Des Dev Ther 5:175–181
Chauviere G, Bouteille B, Enanga B, de Albuquerque C, Croft SL, Dumas M et al (2003) Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead. J Med Chem 46(3):427–440
Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA (2006a) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20(10–11):647–671
Dixon SL, Smondyrev AM, Rao SN (2006b) PHASE: a novel approach to pharmacophore modeling and 3D database searching. Chem Biol Drug Des 67(5):370–372
Enanga B, Ariyanayagam MR, Stewart ML, Barrett MP (2003) Activity of megazol, a trypanocidal nitroimidazole, is associated with DNA damage. Antimicrob Agents Chemother 47(10):3368–3370
Goldman P (1982) The development of 5-nitroimidazoles for the treatment and prophylaxis of anaerobic bacterial infections. J Antimicrob Chemother 10(Suppl A):23–33
Linares GE, Ravaschino EL, Rodriguez JB (2006) Progresses in the field of drug design to combat tropical protozoan parasitic diseases. Curr Med Chem 13(3):335–360
Maeda K, Osato T, Umezawa H (1953) A new antibiotic, azomycin. J Antibiot (Tokyo) 6(4):182
Mahipal, Tanwar OP, Karthikeyan C, Moorthy NS, Trivedi P (2010) 3D QSAR of aminophenyl benzamide derivatives as histone deacetylase inhibitors. Med Chem 6(5):277–285
Marrapu VK, Srinivas N, Mittal M, Shakya N, Gupta S, Bhandari K (2011) Design and synthesis of novel tetrahydronaphthyl azoles and related cyclohexyl azoles as antileishmanial agents. Bioorg Med Chem Lett 21(5):1407–1410
Matter A, Keller TH (2008) Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions. Drug Discov Today 13(7–8):347–352
Miyamoto Y, Kalisiak J, Korthals K, Lauwaet T, Cheung DY, Lozano R et al (2013) Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity. Proc Natl Acad Sci USA 110(43):17564–17569
Papadopoulou MV, Trunz BB, Trunz BB, Bloomer W, Bloomer WD, McKenzie C, McKenzie CF, Wilkinson SR, Prasittichai C, Prasittichai CF et al (2011) Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents. J Med Chem 54(23):8214–8223
Perez-Molina JA, Sojo-Dorado J, Norman F, Monge-Maillo B, Diaz-Menendez M, Albajar-Vinas P et al (2013) Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment. Acta Trop 127(2):101–104
Pink R, Hudson A, Mouries MA, Bendig M (2005) Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov 4(9):727–740
Torreele E, Bourdin TB, Tweats D, Kaiser M, Brun R, Mazue G et al (2010) Fexinidazole—a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 4(12):e923
Verma RP, Hansch C (2010) QSAR modeling of taxane analogues against colon cancer. Eur J Med Chem 45(4):1470–1477
Wilkinson SR, Bot C, Kelly JM, Hall BS (2011) Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr Top Med Chem 11(16):2072–2084
Conflict of interest
Authors declare that they have no conflict of interest by any means with respect to the instant research manuscript.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kumar, S., Agrawal, R. & Bawa, S. Comparative atom-based 3D QSAR study of 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines analogs for its anti-trypanosomal activities. Med Chem Res 24, 22–31 (2015). https://doi.org/10.1007/s00044-014-1085-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-014-1085-y